Table 3 Comparison of 1 year treatment response between the strategic treatment group and unmatched treatment group
Variables | Strategic treatment (n=17) | mismatched (n=17) | p-value |
|---|---|---|---|
Month 6 | |||
⊿TJC (M6-BL) | − 6 (− 8, − 4.5) | − 5 (− 11, − 2.5) | 0.9172 |
⊿SJC (M6-BL) | − 4 (− 7, − 2) | − 4 (− 10.5, − 2) | 0.8086 |
⊿DAPSA (M6-BL) | − 18.6 (− 27.3, − 13.7) | − 18.4 (− 32.4, − 13.3) | 0.9314 |
% decrease, SDAI | − 77.7 (− 89.9, − 71.4) | − 74.0 (− 82.3, − 53.2 | 0.1432 |
Proportion of REM, n (%) | 7 (41.1) | 3 (17.6) | 0.2587 |
Proportion of REM/LDA, n (%) | 17 (100) | 14 (82.3) | 0.1136 |
Minimal Disease Activity | 12 (70.6) | 4 (25.3) | 0.0075* |
% improvement, PASI | 86.0 (53.1, 100) | 100 (17.6, 100) | 0.9809 |
PASI90, n (%) | 7/15 (46.7) | 9/14 (64.2) | 0.9469 |
PASI75, n (%) | 7/15 (46.7) | 9/14 (64.2) | 0.9469 |
Month 12 | |||
⊿TJC (M12-BL) | − 6 (− 8.5, − 3) | − 5 (− 11.5, − 2) | 0.9175 |
⊿SJC (M12-BL) | − 4 (− 6, − 1.5) | − 5 (− 11.5, − 2) | 0.4365 |
⊿DAPSA | − 18.4 (− 27.3, − 12.9) | − 19.45 (− 33.6, − 10.5) | 0.8228 |
% decrease, DAPSA (M12) | − 87.4 (− 97.1, − 75.4) | − 72.0 (− 89.2, − 44.7) | 0.0605 |
Proportion of REM, n (%) | 10 (58.8) | 4 (25.3) | *0.0399* |
Proportion of REM/LDA, n (%) | 15 (88.2) | 13 (76.4) | 0.3281 |
Minimal Disease Activity | 14 (82.3) | 7 (41.2) | *0.0162* |
% improvement, PASI | 92.7 (51.7, 100) | 100 (72.7, 100) | 0.3794 |
PASI90, n (%) | 9/15 (60) | 10/14 (71.4) | 0.8502 |
PASI75, n (%) | 9/15 (60) | 11/14 (78.5) | 0.9320 |